K2 Principal Fund, L.P. Silverback Therapeutics, Inc. Transaction History
K2 Principal Fund, L.P.
- $210 Million
- Q3 2024
A detailed history of K2 Principal Fund, L.P. transactions in Silverback Therapeutics, Inc. stock. As of the latest transaction made, K2 Principal Fund, L.P. holds 120,000 shares of SBTX stock, worth $0. This represents 0.0% of its overall portfolio holdings.
Number of Shares
120,000
Previous 143,900
16.61%
Holding current value
$0
Previous $0
NaN%
% of portfolio
0.0%
Previous 0.0%
Shares
10 transactions
Others Institutions Holding SBTX
# of Institutions
163Shares Held
62.7MCall Options Held
872KPut Options Held
589K-
Deerfield Management Company, L.P. (Series C) New York, NY11.1MShares$00.0% of portfolio
-
Ra Capital Management, L.P. Boston, MA10.9MShares$00.0% of portfolio
-
Orbimed Advisors LLC San Diego, CA8.29MShares$00.0% of portfolio
-
Black Rock Inc. New York, NY4.08MShares$00.0% of portfolio
-
Sr One Capital Management, LP4.01MShares$00.0% of portfolio
About Silverback Therapeutics, Inc.
- Ticker SBTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 35,473,800
- Description
- Silverback Therapeutics, Inc., a biopharmaceutical company, develops tissue-targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases. The company offers SBT8230 to treat chronic hepatitis B virus infection by eliciting an anti-viral immune response by targeting TLR8 activation to the liver. Silverba...